$REPL has been mentioned 23 times over the past 12 months by 2 distinct FinTwit voices, with the first mention appearing on August 26, 2025. Adam Feuerstein (@adamfeuerstein) dominates discussion of Replimune Group with 29 mentions, while Jacob Plieth (@jacobplieth) has contributed 5 mentions. The most recent activity occurred on July 7, 2026, when Feuerstein reported that an FDA advisory committee meeting for $REPL's RP1 candidate had been scheduled for July 30, 2026.

Biotech sector discourse has driven the majority of $REPL mentions in FinTwit. Feuerstein's coverage has focused on regulatory developments, including the timing and proceedings of FDA advisory committee meetings for the RP1 program. The conversation reflects investor interest in the company's clinical trial progression and regulatory pathway, with Feuerstein tracking multiple comparable adcom meetings across the broader biotech space during this period.